IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: A prospective cohort study

Stroke

Volumn 28, Issue 9, 1997, Pages 1660-1665

  Levine, Steven R ^a   Salowich Palm, Leeza ^b   Sawaya, Kara L ^b   Perry, Mary ^a   Spencer, H J ^a   Winkler, H Jason ^b   Alam, Zarina ^b   Carey, John L ^a  

^a HENRY FORD HOSPITAL   (United States)

^b NONE

Author keywords

Antibodies, anticardiolipin; Antibodies, antiphospholipid; Epidemiology; Lupus coagulation inhibitor; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; STEROID;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0030874725     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.9.1660     Document Type: Article

References (34)

1. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997-1002.
2. Camerlingo M, Casto L, Censori B, Drago G, Frigeni A, Ferraro B, Servalli MC, Radice E, Mamoli A. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand. 1995;92:60-71.
3. Brey RL, Hart RG, Sherman DG, Tegeler CT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990; 40:1190-1196.
4. Ford SE, Kennedy LA, Ford PM. Clinico-pathological correlations antiphospholipid antibodies. Arch Pathol Lab Med. 1994;118: 491-495.
5. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulant and antibodies to phospholipids. JAMA. 1988;259:550-554.
6. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49: 193-280.
7. Harris EN (coordinator). The Second International Anticardiolipin Workshop/The Kingston Antiphospholipid Study (KAPS). Am J Clin Pathol. 1990;94:476-484.
8. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: Isotope distribution and phospholipid specificity. Ann Rheum Dis. 1987;46:1-6.
9. Antiphospholipid Antibodies in Stroke Study (APASS) group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-2073.
10. Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B, Perry M, Havstad S, Carey J. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995;38:119-124.
11. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
12. Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146:2153-2156.
13. Branch DW. Outcome of treated pregnancies in women with Antiphospholipid Syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:614-620.
14. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke. 1995;26:160. Abstract.
15. Antiphospholipid Antibodies in Stroke Study (APASS) group. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 1997;47:91-94.
16. Tan EN, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum. 1982;25:1271-1277.
17. Special Report from the National Institute of Neurologic Disorders and Stroke (Whisnant JP, chairman). Classification of cerebrovascular diseases, III. Stroke. 1990;21:637-676.
18. Dolen WK. Detection limits and receiver operating characteristic curve analysis in the evaluation of specific IgE assays. Allergy Proc. 1994;15:319-322.
19. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data analytic approaches and some additional considerations. Stat Med. 1993;12:1293-1316.
20. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiving operating characteristic curve analysis. Ann Clin Biochem. 1993;30:521-539.
21. Levine SR. Antiphospholipid antibodies and the nervous system: clinical features, mechanisms and treatment. Semin Neurol. 1994; 14:168-178.
22. Gharavi AE. IgG subclass and light chain distribution of anticardiolipin and antiDNA antibodies in systemic lupus erythematosus. Ann Rheum Dis. 1988;47:286-290.
23. Sammaritano LR. Significance of aPL IgG subclasses. Lupus. 1996; 5:436-439.
24. Campbell AL, Piperangeli SS, Weilhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemostat. 1995;73: 529-534.
25. Hughes MD. Regression dilution in the proportional hazards model. Biometrics. 1993;49:1056-1066.
26. Escalante A, Brey RL, Mitchell BD, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med. 1995;98: 559-565.
27. Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi G, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian registry. Am J Med. 1996;100:530-536.
28. Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol. 1993;29:82-87.
29. Lockshin MD. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985;313:152-156.
30. Silver RM. Anticardiolipin antibodies: clinical consequences of low titer. Obstet Gynecol. 1996;87:494-500.
31. The Warfarin-Aspirin Recurrent Stroke Study (WARSS), The Antiphospholipid Antibodies and Stroke Study (APASS). The Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS). The Hemostatic System Activation Study (HAS). The Genes in Stroke (GENESIS) Study. The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis. 1997;7:100-112.
32. Matsuura E. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885-3891.
33. Galli M. Anticardiolipin antibodies directed not to cardiolipin but to a plasma cofactor. Lancet. 1990;335:1544-1547.
34. 2-glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol. 1995;34:1031-1036.